Biologicals gained attention over the past decades thanks to their therapeutic success especially in oncology. In the EU vision of personalised treatment, the right treatment should be provided to the right patient and at the right dose and at the right time to increase chances of successful therapy, reduce toxicity and ultimately increase cost-effectiveness.